11/10/2018 06:00:21

NEOVACS ANNOUNCES THE CONTINUATION OF THE DEVELOPMENT OF ITS IFNalpha KINOID IN SOUTH KOREA WITH ITS PARTNER CHONG KUN DANG (CKD) PHARMACEUTICALS

PRESS RELEASE

·

PRESS RELEASE

·

PRESS RELEASE

NEOVACS ANNOUNCES THE CONTINUATION OF THE DEVELOPMENT OF ITS IFN

alpha

KINOID IN SOUTH KOREA WITH ITS PARTNER CHONG KUN DANG (CKD) PHARMACEUTICALS

Both partners have agreed to prepare the filing for an Orphan Drug Designation (ODD)

Paris and Boston, the 11th of October 2018 - 07:00 AM CEST- Neovacs (Euronext Growth Paris ALNEV), leader in active immunotherapy for the treatment of auto-immune diseases, today announces the continuation of the development of its IFNalpha Kinoid in South Korea with its partner Chong Kun Dang (CKD) Pharmaceutical Corp, on the basis of the licensing agreement signed in December 2015, for a potential overall value of 5M€. This agreement covers the development and the commercialization of IFNalpha Kinoid in South Korea for Lupus and Dermatomyositis indications.

Within this agreement both partners have agreed to prepare the filing for an "ODD" in South Korea, based on the results of the Phase IIb trial in Lupus with IFNalpha Kinoid.

Neovacs had already received in 2016 an "Investigational New Drug" (IND) of South Korean Health authorities to include 5 investigational centers in its global Phase IIb trial for IFNalpha Kinoid. Neovacs was able therefore to gain the support of Korean Opinion Leaders in Lupus for its innovative therapeutic approach and to include Korean patients in the study.

« We are pleased with these results which represent a major progress in the research of a treatment for Lupus and the time is approaching when we will be able to offer a satisfying treatment to patients. We are satisfied to continue this partnership and will now make our best efforts to accelerate the development of IFN

alpha

Kinoid in South Korea

within the specific status of this indication in the Korean legislation » declares Young Joo Kim, President of CKD»

« We are delighted that our Korean partner shares our appraisal of the trial results and are confident for the future development of IFNalpha Kinoid in South Korea » concludes Miguel Sieler, CEO of Neovacs.

Neovacs will receive potentially up to 5 million euros in total under this license agreement in sequenced payments, based on the achievement of certain milestones, which include the Phase IIb results.

About Chong Kun Dang Pharmaceutical Corp.

Founded in 1941, CKD is a fully integrated pharmaceutical company employing over 2,000 people. It is one of the leading local pharma companies in Korea and through in-licensing and in-house R&D, it has significantly contributed to improving health and quality of life of people mainly in Korea for more than 70 years. Domestically, it has a strong presence in cardiovascular and immunosuppressant areas and has local offices established in Vietnam and Indonesia. As a leading pharma in Immunosuppressants in Korea, CKD continues to strengthen its major therapeutic area by its R&D capability and licensing-in innovative drugs from business partners worldwide. https://www.ckdpharm.com/eng/company

About Neovacs

Listed on Euronext Growth since 2010, Neovacs is today a leading biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases. On the basis of the company's proprietary technology for inducing a polyclonal immune response (covered by four patent families that potentially run until 2032) Neovacs is focusing its clinical development efforts on IFNalpha Kinoid, an immunotherapy being developed for the indication of lupus, dermatomyositis and also in preclinical trial for Type 1 diabetes. Neovacs is also conducting preclinical development works on other therapeutic vaccines in the fields of auto-immune diseases, oncology and allergies. The goal of the Kinoid approach is to enable patients to have access to safe treatments with efficacy that is sustained in these life-long diseases. www.neovacs.fr

Contacts

NEOVACS - Corporate Communication & Investor Relations

Charlène Masson

+33 1 53 10 93 00

cmasson@neovacs.com

Press release


This announcement is distributed by West Corporation on behalf of West Corporation clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: NEOVACS via Globenewswire

Attachment: Press release.pdf
Del

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
12 Feb
VELO
Hvis agendaen er at komme i en god position for en samlet overtagelse - er de vel godt på vej. I hve..
31
13 Feb
VELO
Her er nogle spørgsmål som jeg ønsker besvaret. Håber i andre vil bidrage med flere spørgsmål som JP..
24
12 Feb
PNDORA
Uden at skulle fremsætte nogen konspirationsteorier så finder jeg det personligt ganske interasant a..
23
12 Feb
GOMX
I får det seriøst til at lyde somom GomX er på vej ned og snakker dommedag 😂! Hallo bois!! Det førs..
20
15 Feb
VELO
Jeg kan se på FB-gruppen at er der en diskussion omkring præparatet fra Hansa Medical det evt. ramme..
19
17 Feb
VWS
  Jeg har nu haft lidt tid til at læse det seneste årsregnskab fra Vestas. Jeg har forsøgt at opsumm..
18
15 Feb
VELO
Jeg har solgt mine Veloxis-aktier, for der er nogle mekanismer i stigningerne i både Chemometec og i..
18
11 Feb
VWS
MHI Vestas named as Preferred Supplier for 476 MW Baltic Eagle project in Germany http://www.mhivest..
18
12 Feb
PNDORA
Fuldstændig uenig.Noget af Pandoras fald er absolut berettiget, ingen tvivl om det!   MEN.Pandora ha..
16
11 Feb
DSV
Der er nogen i denne her tråd, der burde skamme sig, og derefter lære at holde deres ubegavede ringe..
15

HSBC Bank Plc : Form 8.5 (EPT/RI) - Lonmin PLC

22/02/2018 10:54:53
FORM 8.5 EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Name of exempt principal trader: HSBC BANK PLC (b) Name of offeror/offeree i..

Rathbone Brothers Plc : Preliminary announcement of 2017 results

Related news
22/02/2018 07:00:19
Funds under management up 14.3% to £39.1 billionThis is a preliminary statement of annual results published in accordance with FCA Listing Rule 9.7A. It covers the year ended 31 December 2017. Mark Nicholls, Chairman of Rathbone Brothers Plc, said: "UK and global investment markets performed well in 2017, with some indices reaching record levels towards the end of the year. This outcome has b..

Elliott Capital Advisors, L.P : Form 8.3 - GKN Plc

Related news
21/02/2018 15:25:10
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser: Elliott Capital Advisors, L.P. (for itself and related general partners ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
CLASS ACTION UPDATE for UXIN, WRCDF, WCAGY and GE: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
2
CLASS ACTION UPDATE for XRAY, NVDA, AGN and YRIV: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
3
CLASS ACTION UPDATE for IMMU, DBVT, MU and TYME: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
4
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of YRCW, TYME, UXIN and TAP
5
CLASS ACTION UPDATE for AXGN, TYME and MHLD: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
18 February 2019 03:17:26
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: ReleaseBuild_20190215.1 - EUROWEB7 - 2019-02-18 04:17:26 - 2019-02-18 03:17:26 - 1000 - Website: OKAY